libenzapril

Subscribe to Selected New Research on libenzapril

5 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: structure given in first source

Also Known As:

CGS 16617; CGS-16617; 1H-1-Benzazepine-1-acetic acid, 3-((5-amino-1-carboxypentyl)amino)-2,3,4,5-tetrahydro-2-oxo-

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Benzazepines: 2

libenzapril: 5

Related Diseases

1.	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/01/1988 - "Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat." 01/01/1988 - "The present study was designed to examine the effects of two new angiotensin-converting enzyme (ACE) inhibitors, CGS 14831 and CGS 16617 (3 mg/kg i. v. 1 min prior to occlusion and 4 and 24 h after occlusion), on myocardial ischemic (MI) damage and left-ventricular hypertrophy in rats" Get all the results and reference details, order at left...
2.	Hypertension (High Blood Pressure) 01/01/1993 - "A previous communication from this laboratory reported that brain uptake of libenzapril, a small polar molecule, was enhanced in chronic hypertension (1)" 02/01/1992 - "Effect of chronic hypertension on the blood-brain barrier permeability of libenzapril." Get all the results and reference details, order at left...
3.	Hemorrhagic Shock 07/01/1987 - "The effect of a specific inhibitor of thromboxane (Tx) A2 synthesis, CGS-13080, a new angiotensin converting enzyme inhibitor, CGS-16617, and a combination of both drugs was studied in hemorrhagic shock in rats" Get all the results and reference details, order at left...
4.	Shock 07/01/1987 - "CGS-16617 (1 microgram/kg) attenuated significantly the pressor response to angiotensin I throughout the shock period" Get all the results and reference details, order at left...
5.	Myocardial Infarction 07/01/1987 - "A specific inhibitor of thromboxane A2 (TxA2) synthesis, CGS-12970, a new angiotensin-converting enzyme (ACE) inhibitor, CGS-16617, and a combination of both agents were evaluated for their ability to reduce the extension of myocardial infarct size in rats" Get all the results and reference details, order at left...
8 Diseases and 5 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
2.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
3.	benazeprilat
4.	Thromboxane A2 (A2, Thromboxane)
5.	Cathepsin D
6.	Angiotensin I
7.	3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid
8.	pirmagrel
8 Drugs and Important Bio-Agents and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>